Versant's Repare raises $82M to trial synthetic lethality drugs
Repare Therapeutics has raised an $82.5 million series B round to take synthetic lethality drugs into humans. The Versant Ventures-founded biotech plans to start testing ATR inhibitor RP-3500 in the clinic next year.